X4 PHARMACEUTICALS
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.
X4 PHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Health Care Pharmaceutical Therapeutics
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.x4pharma.com
Total Employee:
51+
Status:
Active
Contact:
+1 857 529 8300
Email Addresses:
[email protected]
Total Funding:
174.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Redpin Therapeutics
Redpin Therapeutics is a preclinical stage gene therapy company that develops chemogenetics platform designed for nervous system diseases.
Aravive Biologics
Aravive Biologics is a clinical-stage biotechnology company that focuses on developing therapies that target important survival pathways.
Regenerative Bio
Regenerative Bio is the world's first anti-aging biotechnology company driven by artificial intelligence and cloud supercomputing.
Rhoshan Pharmaceuticals
Rhoshan Pharmaceuticals is an early-stage life sciences company focused on developing injectable presentations of commonly used oral drugs.
Reven Pharmaceuticals
Reven Pharmaceuticals is a clinical-stage company providing solutions for the treatment of vascular and metabolic-related conditions.
Rubius Therapeutics
Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics.
Nautilus Biotechnology
Nautilus Biotechnology offers a high-throughput, low-cost platform for analyzing and quantifying the human proteome.
nQ Medical
nQ Medical is a neurotechnology company allowing Data Defined Disease Management via digital biomarkers using AI.
NRx Pharmaceuticals
NRx Pharmaceuticals is a pharmaceutical company developing therapeutics for the treatment of central nervous system disorders.
NorthSea Therapeutics
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
NuvOx Pharma
NuvOx Pharma is developing a nanotechnology for oxygen delivery, DDFPe, which is a best-in-class drug that is Phase II ready in stroke.
Maxona Pharmaceuticals
Maxona is a pharmaceutical company that develops and commercializes a portfolio of novel therapeutics for the treatment of pain.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Landos Biopharma
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
Lyndra Therapeutics
Lyndra Therapeutics is a novel technology platform reinventing medicine for a healthier world.
Alzheon
Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
amcure
amcure is a clinical-stage company develops peptide-based compounds for the treatment of highly metastatic forms of squamous cancer.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Avicanna
Avicanna is a biopharmaceutical company that focuses on the development of the medical cannabis space.
Alvine Pharmaceuticals
Alvine Pharmaceuticals is a biotechnology company developing therapeutics for autoimmune and inflammatory diseases.
Aerpio Pharmaceuticals
Aerpio Pharmaceuticals is a biotechnology company that develops small molecules and monoclonal antibodies for vascular diseases treatment.
First Wave BioPharma
First Wave BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies.
Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients.
Enanta Pharmaceuticals
Enanta Pharmaceuticals is an R&D company discovers, develops and promotes of small molecule drugs in the areas of anti-infective.
Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.
BriaCell Therapeutics
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
Iterion Therapeutics
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics.
BioEclipse Therapeutics
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology.
BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.
Bio-Path Holdings
Bio-Path Holdings is a biotechnology company developing therapeutic products for the liposomal delivery of nucleic acids in cancer patients.
Fusion Pharmaceuticals
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals.
Faraday Pharmaceuticals
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.
Tremeau Pharmaceuticals
A privately funded clinical stage company based Massachusetts .
Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer.
True North Therapeutics
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases.
Third Harmonic Bio
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Juno Therapeutics
Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Janus Biotherapeutics
Janus Biotherapeutics, an autoimmunity therapeutics company, develops orally available compounds for the treatment of autoimmune diseases.
Korro Bio
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
K36 Therapeutics
K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
Sorriso Pharmaceuticals
Sorriso Pharmaceuticals is a biotech firm developing disease-modifying antibodies for the treatment of inflammatory diseases.
Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a discovery company developing a new class of pharmaceuticals called small molecule nucleic acid hybrids.
Signpath Pharma
Signpath Pharma is a biotechnology company developing therapeutics using curcuminoids extracted from the root of the Curcuma longa plant.
Satsuma Pharmaceuticals
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product.
DCPrime
DCPrime is a clinical stage company which develops novel cancer immunotherapies based on its DCOne platform technology.
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
ImaginAb
ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
IMMvention Therapeutix
IMMvention Therapeutix is a biotechnology company developing novel small molecule pan-inflammasome inhibitors for inflammatory diseases.
GamaMabs Pharma
GamaMabs Pharma is a clinical-stage immuno-oncology company that developes optimized therapeutic antibodies for the treatment of cancer.
Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers.
Osivax
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a biotechnology company developing novel therapeutics for the treatment of cancer.
ZZ Biotech
A clinical stage company developing innovative biologic treatments for ischemic stroke.
CNS Pharmaceutical
CNS Pharmaceutical is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors.
CiVi Biopharma
CiVi Biopharma is a clinical stage research and development biotechnology company whose mission is to create novel cardiovascular.
Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics.
Clover Biopharmaceuticals
Clover Biopharmaceuticals is a clinical-stage biotechnology company focused on developing vaccines and biologic therapeutic.
Cybrexa Therapeutics
Cybrexa Therapeutics is a cancer therapeutics company developing a new class of small molecule DNA repair.
Calithera Biosciences
Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Cour Pharmaceuticals Development
Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
Prelude
Prelude delivers actionable tools to manage early stage breast cancer with the DCIS test that enables personalized treatment.
PuREC
PuREC is a developer of a culture technology intended to bring efficacy to the treatment process.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-03-13 | Arsanis | Arsanis acquired by X4 Pharmaceuticals | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Equity - X4 Pharmaceuticals
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Post-IPO Equity - X4 Pharmaceuticals
Lumira Ventures
Lumira Ventures investment in Post-IPO Equity - X4 Pharmaceuticals
OrbiMed
OrbiMed investment in Post-IPO Equity - X4 Pharmaceuticals
AXA Investment Managers
AXA Investment Managers investment in Post-IPO Equity - X4 Pharmaceuticals
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Equity - X4 Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - X4 Pharmaceuticals
Altium Capital
Altium Capital investment in Post-IPO Equity - X4 Pharmaceuticals
Driehaus Capital Management
Driehaus Capital Management investment in Post-IPO Equity - X4 Pharmaceuticals
OrbiMed
OrbiMed investment in Post-IPO Equity - X4 Pharmaceuticals
Official Site Inspections
http://www.x4pharma.com Semrush global rank: 4.86 M Semrush visits lastest month: 1.82 K
- Host name: 209.103.196.104.bc.googleusercontent.com
- IP address: 104.196.103.209
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "X4 Pharmaceuticals"
Release Details - investors.x4pharma.com
Dec 31, 2023 Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024 …See details»
X4 Pharmaceuticals - Crunchbase Company Profile
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is …See details»
X4 Pharmaceuticals Company Overview, Contact Details
Nov 08, 2023 | investors.x4pharma.com X4 Pharmaceuticals hired R. Keith Woods as Board of Directors on Oct 18th '23. BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 …See details»
Release Details - X4 Pharmaceuticals, Inc.
Dec 31, 2022 For more information, please visit our website at www.x4pharma.com. Contacts: Daniel Ferry (investors) Managing Director, LifeSci Advisors [email protected] (617) …See details»
X4 Pharmaceuticals, Inc. - AnnualReports.com
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on …See details»
X4 Pharmaceuticals, Inc. (XFOR) Company Profile & Overview
Oct 11, 2024 X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the …See details»
X4 Pharmaceuticals - Craft
Oct 29, 2024 X4 Pharmaceuticals has 5 employees across 2 locations and $3 m in annual revenue in FY 2020. See insights on X4 Pharmaceuticals including office locations, …See details»
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ …
Apr 29, 2024 The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a …See details»
X4 Pharmaceuticals Announces Positive Interim Clinical Data from ...
Jun 27, 2024 X4 Pharmaceuticals. 100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G …See details»
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results …
Nov 9, 2023 In anticipation of a potential second quarter 2024 U.S. launch of mavorixafor in WHIM syndrome, X4 has continued to build out its go-to market organization, with key hires …See details»
X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance Canada
Find the latest X4 Pharmaceuticals, Inc. (XFOR) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results …
BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today …See details»
X4 Pharmaceuticals, Inc. (XFOR) - Stock Analysis
5 days ago Website https://www.x4pharma.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 4 analysts, the average rating for XFOR …See details»
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results …
The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast and …See details»
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results …
May 7, 2024 Recent and Key Anticipated Upcoming Milestones. In late April 2024, X4 announced that the U.S. Food and Drug Administration (FDA) approved XOLREMDI …See details»
X4 Pharmaceuticals Announces Positive Results from
Nov 13, 2024 The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA.See details»
Release Details - X4 Pharmaceuticals, Inc.
For more information, please visit www.x4pharma.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities …See details»
Mavorixafor for Patients With Chronic Neutropenic Disorders: …
Contact: [email protected] CN, chronic neutropenic. ... organization, and other vendors. They would also like to acknowledge the medical writing assistance of …See details»
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare ...
Nov 14, 2024 For more information, please visit our website at www.x4pharma.com. Company Contact: José Juves Head of Corporate & Patient Affairs [email protected]. Investor …See details»